140 related articles for article (PubMed ID: 14689754)
1. Gene therapy for human immunodeficiency virus infection in the humanized SCID mouse model.
Touraine JL; Sanhadji K; Sembeil R
Isr Med Assoc J; 2003 Dec; 5(12):863-7. PubMed ID: 14689754
[TBL] [Abstract][Full Text] [Related]
2. Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4(+) T cells from virus-induced depletion in SCID mice transplanted with human cells.
Lapenta C; Santini SM; Proietti E; Rizza P; Logozzi M; Spada M; Parlato S; Fais S; Pitha PM; Belardelli F
Virology; 1999 Oct; 263(1):78-88. PubMed ID: 10544084
[TBL] [Abstract][Full Text] [Related]
3. Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice.
Sanhadji K; Grave L; Touraine JL; Leissner P; Rouzioux C; Firouzi R; Kehrli L; Tardy JC; Mehtali M
AIDS; 2000 Dec; 14(18):2813-22. PubMed ID: 11153662
[TBL] [Abstract][Full Text] [Related]
4. [In vitro and in vivo inhibition of HIV1 replication by retroviral transfer of interferon alpha, beta, or gamma genes: application to gene therapy of AIDS].
Leissner P; Calenda V; Marigliano M; Sanhadji K; Touraine JL; Pavirani A; Mehtali M
Ann Biol Clin (Paris); 1998; 56(2):167-73. PubMed ID: 9754242
[TBL] [Abstract][Full Text] [Related]
5. Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication.
Caputo A; Rossi C; Bozzini R; Betti M; Grossi MP; Barbanti-Brodano G; Balboni PG
Gene Ther; 1997 Apr; 4(4):288-95. PubMed ID: 9176513
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
Mautino MR; Morgan RA
Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.
Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP
Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713
[TBL] [Abstract][Full Text] [Related]
8. siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS.
Akkina R; Banerjea A; Bai J; Anderson J; Li MJ; Rossi J
Anticancer Res; 2003; 23(3A):1997-2005. PubMed ID: 12894572
[TBL] [Abstract][Full Text] [Related]
9. The SCID-hu mouse: an in-vivo model for HIV-1 pathogenesis and stem cell gene therapy for AIDS.
Jamieson BD; Aldrovandi GM; Zack JA
Semin Immunol; 1996 Aug; 8(4):215-21. PubMed ID: 8883144
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-)) mouse model.
ter Brake O; Legrand N; von Eije KJ; Centlivre M; Spits H; Weijer K; Blom B; Berkhout B
Gene Ther; 2009 Jan; 16(1):148-53. PubMed ID: 18668146
[TBL] [Abstract][Full Text] [Related]
11. Potent knock down of HIV-1 replication by targeting HIV-1 Tat/Rev RNA sequences synergistically with catalytic RNA and DNA.
Sood V; Unwalla H; Gupta N; Chakraborti S; Banerjea AC
AIDS; 2007 Jan; 21(1):31-40. PubMed ID: 17148965
[TBL] [Abstract][Full Text] [Related]
12. Potent inhibition of HIV-1 gene expression and TAT-mediated apoptosis in human T cells by novel mono- and multitarget anti-TAT/Rev/Env ribozymes and a general purpose RNA-cleaving DNA-enzyme.
Unwalla H; Chakraborti S; Sood V; Gupta N; Banerjea AC
Antiviral Res; 2006 Nov; 72(2):134-44. PubMed ID: 16790281
[TBL] [Abstract][Full Text] [Related]
13. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery.
Swan CH; Bühler B; Steinberger P; Tschan MP; Barbas CF; Torbett BE
Gene Ther; 2006 Oct; 13(20):1480-92. PubMed ID: 16738691
[TBL] [Abstract][Full Text] [Related]
14. RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy.
Li M; Li H; Rossi JJ
Ann N Y Acad Sci; 2006 Oct; 1082():172-9. PubMed ID: 17145937
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of HIV replication: a powerful antiviral strategy by IFN-beta gene delivery in CD4+ cells.
Brule F; Khatissian E; Benani A; Bodeux A; Montagnier L; Piette J; Lauret E; Ravet E
Biochem Pharmacol; 2007 Sep; 74(6):898-910. PubMed ID: 17662695
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy clinical trials for HIV.
Statham S; Morgan RA
Curr Opin Mol Ther; 1999 Aug; 1(4):430-6. PubMed ID: 11713756
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue.
Goldstein H; Pettoello-Mantovani M; Anderson CM; Cordelier P; Pomerantz RJ; Strayer DS
J Infect Dis; 2002 May; 185(10):1425-30. PubMed ID: 11992277
[TBL] [Abstract][Full Text] [Related]
18. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
19. Technology evaluation: StealthVector (HIV) Enzo.
Günzburg W; Mhashilkar AM; Hindi M
Curr Opin Mol Ther; 1999 Oct; 1(5):651-7. PubMed ID: 11249672
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients.
Macpherson JL; Boyd MP; Arndt AJ; Todd AV; Fanning GC; Ely JA; Elliott F; Knop A; Raponi M; Murray J; Gerlach W; Sun LQ; Penny R; Symonds GP; Carr A; Cooper DA
J Gene Med; 2005 May; 7(5):552-64. PubMed ID: 15655805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
